Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company

Sandoz Plans USD 90 Million Biosimilar Development Center in Slovenia by 2026

Fineline Cube Jul 21, 2023

The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has announced plans to construct a biosimilar...

Company Deals Policy / Regulatory

Johnson & Johnson Files Lawsuit Against US Government’s Drug Pricing Negotiation Authority

Fineline Cube Jul 21, 2023

United States-based Johnson & Johnson (J&J, NYSE: JNJ) has filed a lawsuit this week, challenging...

Company Deals

GSK Partners with LimmaTech for Further Development of Quadrivalent Shigellosis Vaccine

Fineline Cube Jul 21, 2023

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has licensed its quadrivalent bioconjugate shigellosis vaccine candidate...

Company

Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip

Fineline Cube Jul 21, 2023

US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second...

Company Drug

Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug

Fineline Cube Jul 21, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval...

Company Deals

Livzon Pharmaceutical Secures Licensing Agreement for Synergy Pharma’s HHT120 in Greater China

Fineline Cube Jul 21, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with fellow Chinese...

Company Deals Digital

Alibaba Health and Daiichi Sankyo Partner to Innovate in Digital Healthcare Services

Fineline Cube Jul 20, 2023

China’s Alibaba Health Information Technology Ltd (HKG: 0241) has entered into a strategic partnership with...

Drug

Pfizer’s GBS Vaccine Candidate GBS6 Shows Promise in Phase II Maternal Immunization Study

Fineline Cube Jul 20, 2023

Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B...

Legal / IP Policy / Regulatory

US Merger Guidelines Updated: Public Comment Sought on Antitrust Law Changes

Fineline Cube Jul 20, 2023

The United States has published an update to its merger and acquisition guidelines, seeking public...

Company Drug

Merck and Telix Pharmaceuticals Initiate Phase I Study for CAIX-Expressing Tumors Therapy

Fineline Cube Jul 20, 2023

A Phase I study assessing the combination of German-major Merck’s (NYSE: MRK) DNA-PK inhibitor, peposertib,...

Company Drug

Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB

Fineline Cube Jul 20, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...

Company Drug

Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine

Fineline Cube Jul 20, 2023

Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I...

Company Drug

Chipscreen Pharmaceutical’s Epidaza Granted Priority Status for DLBCL Treatment in China

Fineline Cube Jul 20, 2023

The Center for Drug Evaluation (CDE) website has announced that Shenzhen Chipscreen Biosciences Co., Ltd’s...

Company Drug

HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer

Fineline Cube Jul 20, 2023

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib)...

Company Drug

Kintor Pharmaceutical Initiates Long-Term Safety Trial for Androgenetic Alopecia Treatment KX-826

Fineline Cube Jul 20, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the start of the long-term safety trial...

Company Deals

Hybribio Ltd and United Imaging Healthcare Form Strategic Partnership to Advance Medical Technology

Fineline Cube Jul 20, 2023

Guangdong-based Hybribio Ltd (SHE: 300639), a leading provider of nucleic acid molecular diagnostic products, has...

Company Deals

Novomics Partners with TopGene to Expand Genomic Testing Services in China

Fineline Cube Jul 20, 2023

South Korea-based molecular diagnostics firm Novomics Co. has announced a strategic partnership with China-based Hubei...

Company

Stemirna Therapeutics Halts mRNA Vaccine Factory Construction Amid Low Demand

Fineline Cube Jul 20, 2023

China-based Stemirna Therapeutics Co., Ltd has decided to halt the construction of a factory intended...

Company Deals

BGI Genomics Partners with Thai Entities to Combat Thalassemia through Genomics and Cell Therapy

Fineline Cube Jul 20, 2023

China-based genomics leader BGI Genomics Co., Ltd (SHE: 300676) has entered into a memorandum of...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Receives NMPA Review for ES-SCLC Treatment

Fineline Cube Jul 20, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the National Medical...

Posts pagination

1 … 501 502 503 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.